Business Wire

AL-ADTRAN

17.5.2022 11:32:12 CEST | Business Wire | Press release

Share
Fibernet Builds Competitive 10G Fiber Network with Adtran

Adtran, Inc. , (NASDAQ: ADTN), the leading provider of next-generation multi-gigabit fiber access and fiber extension solutions, today announced Fibernet is leveraging the Adtran 10G Fiber Access Platform to build an XGS-PON fiber network that will connect 50,000 customers in its first phase. Fibernet is leveraging its innovative fiber trenching technology to quickly build a fiber network and is using Adtran’s reliable 10G solutions to deploy competitive, scalable broadband services to households and businesses in Finland.

Fibernet is a new alternative network provider (altnet) in Finland, where much of the country can access 4G mobile broadband coverage. However, increased demand for high-bandwidth, reliable internet means that fiber connections are a necessity. While some established service providers began slowly building expensive fiber networks, Fibernet invested in an innovative fiber trenching approach that allows the altnet to build its network much faster. Fibernet selected the Adtran 10G Fiber Access Platform as its foundation to launch high-quality, competitive broadband services for internet, IPTV, telehealth and more.

“While Fibernet is new to this market, our leaders have deep experience in implementing superior broadband networks. We selected Adtran because of its experience in both the fiber access and altnet markets, and together we make a great team. We are extremely pleased with the support that Adtran has provided in our startup phase,” said Janne Ahola, CEO at Fibernet. “We understand that fiber is the only way to supply fast and reliable network connections that can scale with subscriber demands. Adtran provides a solution that can help us meet those needs today and in the future.”

The Adtran 10G Fiber Access Platform leverages the symmetrical upload and download speeds of XGS-PON technology, which future-proofs the network against growing demand for high-bandwidth cloud and streaming services. Adtran’s supply availability is also a differentiator for Fibernet. In Finland, the ground is frozen for five months each year. The long winters require well-planned building seasons and hardware deliveries must be on schedule during the warmer months. Adtran offers a comprehensive end-to-end access portfolio that allows Fibernet to order most of the hardware from a single vendor to better ensure on-time deliveries.

“Fibernet has a key advantage with its micro-trenching technology that lets it build its fiber network much faster. With Adtran in its network, Fibernet can match that innovation with a 10G fiber access platform that will provide reliable, high-quality services today and grow with them as subscriber demands evolve,” said Stuart Broome, Vice President of Sales, EMEA at Adtran. “The ease of scalability will enable Fibernet to increase capacity and scale services beyond its traditional residential subscriber base to support the connectivity needs of local small- and mid-sized businesses as well.”

For more information about the Adtran 10G Fiber Access Platform , visit www.adtran.com/fiber-access .

About Adtran

Adtran, Inc. is a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are currently in use by service providers, private enterprises, government organizations and millions of individual users worldwide. Find more at Adtran , LinkedIn and Twitter .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release

Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release

As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release

Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye